title: Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant.
abstract: OBJECTIVE
  This study examined whether the CD34(+) cell dose in allografts correlates with the dose of myeloid dendritic cells (mDC) and plasmacytoid DC (pDC), and with DC reconstitution and clinical outcome after a myeloablative HLA-matched transplant.
  
  
  METHODS
  Fifty-three patients were included in this study: 37 who had undergone a granulocyte colony-stimulating factor mobilized peripheral blood stem cells (PBSC) transplant from related donors and 16 who had undergone a marrow transplant from unrelated donors. The number of CD34(+) cells, lin(-)HLA-DR(+)CD11c(+) mDC, lin(-)HLA-DR(+)CD123(+) pDC, CD14(+) monocytes, and CD3(+)CD4(+), CD3(+)CD8(+), CD56(+), and CD19(+) lymphocytes was compared in the graft, as well as in the peripheral blood after transplant, in patients receiving more than versus less than or equal to the median number of CD34(+) cells in PBSC (5.78 x 10(6)/kg) or in marrow (2.8 x 10(6)/kg).
  
  
  RESULTS
  A higher CD34(+) cell dose was associated with larger numbers of mDC in PBSC (p=0.01) and pDC in marrow grafts (p=0.004). However, neither mDC nor pDC recovery after transplant correlated with the number of CD34(+) cells infused. Finally, higher doses of CD34(+) cells appeared to negatively affect (p=0.02) the overall survival in PBSC transplantation and were associated with a trend for higher acute graft-vs-host disease in PBSC and lower acute graft-vs-host disease in marrow transplant.
  
  
  CONCLUSIONS
  CD34(+) cell dose correlates with the dose of different DC subsets in PBSC and marrow grafts, but it does not affect DC reconstitution after transplant. Higher doses of CD34(+) cells in PBSC, but not in marrow, seem to adversely affect survival after transplant.
authors.affiliation: Research Center for Transplant Immunology, Institute of Hematology and Medical Oncology "Seràgnoli," University of Bologna, Bologna, Italy.
authors.forename: Benedetta
authors.initials: B
authors.lastname: Urbini
authors.forename: Mario
authors.initials: M
authors.lastname: Arpinati
authors.forename: Francesca
authors.initials: F
authors.lastname: Bonifazi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Chirumbolo
authors.forename: Sadia
authors.initials: S
authors.lastname: Falcioni
authors.forename: Marta
authors.initials: M
authors.lastname: Stanzani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bandini
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Motta
authors.forename: Giulia
authors.initials: G
authors.lastname: Perrone
authors.forename: Benedetta
authors.initials: B
authors.lastname: Giannini
authors.forename: Sante
authors.initials: S
authors.lastname: Tura
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Damiano
authors.initials: D
authors.lastname: Rondelli
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis*; D016026:Bone Marrow Transplantation / Q000401:mortality; D003713:Dendritic Cells / Q000502:physiology*; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D036102:Peripheral Blood Stem Cell Transplantation / Q000401:mortality; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34